Cargando…

A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer

Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellula...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Ting, Liu, Junyan, She, Li, Chen, Juan, Zhu, Tao, Yin, Jiye, Li, Xi, Li, Xiangping, Zhou, Honghao, Liu, Zhaoqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909948/
https://www.ncbi.nlm.nih.gov/pubmed/31839819
http://dx.doi.org/10.7150/jca.36614
_version_ 1783479025661902848
author Zou, Ting
Liu, Junyan
She, Li
Chen, Juan
Zhu, Tao
Yin, Jiye
Li, Xi
Li, Xiangping
Zhou, Honghao
Liu, Zhaoqian
author_facet Zou, Ting
Liu, Junyan
She, Li
Chen, Juan
Zhu, Tao
Yin, Jiye
Li, Xi
Li, Xiangping
Zhou, Honghao
Liu, Zhaoqian
author_sort Zou, Ting
collection PubMed
description Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellular transport through the binding to cAMP dependent protein kinases (PKAs), cAMP-activated guanine exchange factors (EPACs) and cyclic nucleotide-gated channels functioning in transduction of sensory signals (CNGs). Lung cancer is one of the leading factors of cancer-related death worldwide. Platinum-based chemotherapy is the first-line treatment for advanced lung cancer patients. In addition, surgical treatment, radiation treatment, and molecular targeted therapy are also therapeutic options for lung cancer patients in clinical settings. However, drug resistance and toxicity are the major obstacles that affect chemotherapy outcome and prognosis of lung cancer patients. And the therapeutic efficiency and adverse effects are varying with each individual. In recent years, investigations based on genetic sequencing have revealed the emerging role of ADCY1 mutations in affecting drug efficiency in various cancers such as lung cancer, esophageal cancer and colorectal cancer. The potential function of ADCY1 in chemotherapy resistance is of great importance to be noticed and investigated.
format Online
Article
Text
id pubmed-6909948
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-69099482019-12-15 A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer Zou, Ting Liu, Junyan She, Li Chen, Juan Zhu, Tao Yin, Jiye Li, Xi Li, Xiangping Zhou, Honghao Liu, Zhaoqian J Cancer Review Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellular transport through the binding to cAMP dependent protein kinases (PKAs), cAMP-activated guanine exchange factors (EPACs) and cyclic nucleotide-gated channels functioning in transduction of sensory signals (CNGs). Lung cancer is one of the leading factors of cancer-related death worldwide. Platinum-based chemotherapy is the first-line treatment for advanced lung cancer patients. In addition, surgical treatment, radiation treatment, and molecular targeted therapy are also therapeutic options for lung cancer patients in clinical settings. However, drug resistance and toxicity are the major obstacles that affect chemotherapy outcome and prognosis of lung cancer patients. And the therapeutic efficiency and adverse effects are varying with each individual. In recent years, investigations based on genetic sequencing have revealed the emerging role of ADCY1 mutations in affecting drug efficiency in various cancers such as lung cancer, esophageal cancer and colorectal cancer. The potential function of ADCY1 in chemotherapy resistance is of great importance to be noticed and investigated. Ivyspring International Publisher 2019-11-01 /pmc/articles/PMC6909948/ /pubmed/31839819 http://dx.doi.org/10.7150/jca.36614 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Zou, Ting
Liu, Junyan
She, Li
Chen, Juan
Zhu, Tao
Yin, Jiye
Li, Xi
Li, Xiangping
Zhou, Honghao
Liu, Zhaoqian
A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
title A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
title_full A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
title_fullStr A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
title_full_unstemmed A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
title_short A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
title_sort perspective profile of adcy1 in camp signaling with drug-resistance in lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909948/
https://www.ncbi.nlm.nih.gov/pubmed/31839819
http://dx.doi.org/10.7150/jca.36614
work_keys_str_mv AT zouting aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT liujunyan aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT sheli aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT chenjuan aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT zhutao aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT yinjiye aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT lixi aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT lixiangping aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT zhouhonghao aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT liuzhaoqian aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT zouting perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT liujunyan perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT sheli perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT chenjuan perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT zhutao perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT yinjiye perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT lixi perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT lixiangping perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT zhouhonghao perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer
AT liuzhaoqian perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer